Mahmoud A, Choi P, Sukhwa C, Pintar J, Walch H, Zhao N
bioRxiv. 2025; .
PMID: 40027618
PMC: 11870485.
DOI: 10.1101/2025.02.17.638725.
Berg S, Berg J
Front Immunol. 2025; 15:1493978.
PMID: 39981299
PMC: 11840190.
DOI: 10.3389/fimmu.2024.1493978.
Thibault B, Thole A, DAngelo R, Basset C, Guillermet-Guibert J
Sci Rep. 2025; 15(1):6265.
PMID: 39979449
PMC: 11842864.
DOI: 10.1038/s41598-025-90714-9.
Park M, Shin W, Lim M, Park S, Yoo C, Kim K
Medicine (Baltimore). 2025; 103(47):e40487.
PMID: 39809172
PMC: 11596952.
DOI: 10.1097/MD.0000000000040487.
Lee W, Ko S, Akasaka H, Weigert M, Lengyel E, Naora H
Cancer Cell. 2025; 43(1):69-85.e11.
PMID: 39753138
PMC: 11732717.
DOI: 10.1016/j.ccell.2024.12.004.
Plakin Expression in Serous Epithelial Ovarian Cancer Has the Potential to Impede Metastatic Spread and Epithelial-Mesenchymal Transition: A Comparative Expression Analysis of Immunohistochemical and In Silico Datasets.
Wesley T, Escalona R, Kannourakis G, Ahmed N
Cancers (Basel). 2024; 16(23).
PMID: 39682273
PMC: 11639978.
DOI: 10.3390/cancers16234087.
Tumor specific delivery and radiation-enhanced tumor penetration of mesoporous silica nanoparticles for effective radionuclide therapy of ovarian peritoneal metastasis.
Hargrove D, Ranjbar S, Darji M, Nam S, Dawson R, Katugampola S
Int J Pharm. 2024; 669:125071.
PMID: 39662854
PMC: 11791539.
DOI: 10.1016/j.ijpharm.2024.125071.
Ascitic Shear Stress Activates GPCRs and Downregulates Mucin 15 to Promote OvarianCancer Malignancy.
Mehta G, Horst E, Cotter L, Bonini M, Novak C, Treacher N
Res Sq. 2024; .
PMID: 39483899
PMC: 11527234.
DOI: 10.21203/rs.3.rs-5160301/v1.
NEU4-mediated desialylation enhances the activation of the oncogenic receptors for the dissemination of ovarian carcinoma.
Shi J, Zhou R, Wang S, Liu Y, Tian B, Liu Y
Oncogene. 2024; 43(49):3556-3569.
PMID: 39402373
DOI: 10.1038/s41388-024-03187-x.
Macrophage diversity in cancer dissemination and metastasis.
Mantovani A, Marchesi F, Di Mitri D, Garlanda C
Cell Mol Immunol. 2024; 21(11):1201-1214.
PMID: 39402303
PMC: 11528009.
DOI: 10.1038/s41423-024-01216-z.
SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137.
Kamikawa T, Kimura N, Ishii S, Muraoka M, Kodama T, Taniguchi K
J Immunother Cancer. 2024; 12(10).
PMID: 39401967
PMC: 11474890.
DOI: 10.1136/jitc-2024-009563.
The Role of Circulating Tumor DNA in Ovarian Cancer.
Golara A, Kozlowski M, Cymbaluk-Ploska A
Cancers (Basel). 2024; 16(18).
PMID: 39335089
PMC: 11430586.
DOI: 10.3390/cancers16183117.
Exosomes: Key Factors in Ovarian Cancer Peritoneal Metastasis and Drug Resistance.
Shao M, Gao Y, Xu X, Chan D, Du J
Biomolecules. 2024; 14(9).
PMID: 39334866
PMC: 11430201.
DOI: 10.3390/biom14091099.
Recombinant humanized type III collagen inhibits ovarian cancer and induces protective anti-tumor immunity by regulating autophagy through GSTP1.
Zeng H, Li H, Wang L, You S, Liu S, Dong X
Mater Today Bio. 2024; 28:101220.
PMID: 39290464
PMC: 11405829.
DOI: 10.1016/j.mtbio.2024.101220.
Targeting NETosis: nature's alarm system in cancer progression.
Liang Y, Wu G, Tan J, Xiao X, Yang L, Saw P
Cancer Drug Resist. 2024; 7:28.
PMID: 39143953
PMC: 11322967.
DOI: 10.20517/cdr.2024.24.
Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer.
Ju H, Youn S, Kang J, Whang M, Choi Y, Han M
Biomark Res. 2024; 12(1):80.
PMID: 39135097
PMC: 11318304.
DOI: 10.1186/s40364-024-00632-7.
Integrated miRNA Profiling of Extracellular Vesicles from Uterine Aspirates, Malignant Ascites and Primary-Cultured Ascites Cells for Ovarian Cancer Screening.
Skryabin G, Komelkov A, Zhordania K, Bagrov D, Enikeev A, Galetsky S
Pharmaceutics. 2024; 16(7).
PMID: 39065600
PMC: 11280431.
DOI: 10.3390/pharmaceutics16070902.
Advances in ovarian tumor stem cells and therapy.
Chen B, Liu J
Cell Biochem Biophys. 2024; 82(3):1871-1892.
PMID: 38955927
DOI: 10.1007/s12013-024-01385-8.
Extracellular ATP/P2X7 receptor, a regulatory axis of migration in ovarian carcinoma-derived cells.
Nunez-Rios J, Reyna-Jeldes M, Mata-Martinez E, Campos-Contreras A, Lazcano-Sanchez I, Gonzalez-Gallardo A
PLoS One. 2024; 19(6):e0304062.
PMID: 38870128
PMC: 11175443.
DOI: 10.1371/journal.pone.0304062.
Adipocyte pyroptosis occurs in omental tumor microenvironment and is associated with chemoresistance of ovarian cancer.
Lin C, Liang Y, Tsai H, Wu P, Huang L, Lin Y
J Biomed Sci. 2024; 31(1):62.
PMID: 38862973
PMC: 11167873.
DOI: 10.1186/s12929-024-01051-4.